Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
By Dr. Matthew Watson
TEMPLE CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its first quarter 2021 financial results after the market closes on Thursday May 6, 2021. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.
The rest is here:
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
- AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal... - March 26th, 2024
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - March 26th, 2024
- Gedeon Richter Selects Trial Interactive for Clinical Trial Management - March 26th, 2024
- Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of... - March 26th, 2024
- OXURION announces its presence at the Paris SmallCap event on March 28, 2024. - March 26th, 2024
- Foreløbige tal for 2023 og finansielle forventninger til 2024 - March 26th, 2024
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 26th, 2024
- Praxis Precision Medicines to Host PRAX-628 Program Update - March 26th, 2024
- BioCryst to Present at Upcoming Investor Conferences - March 26th, 2024
- NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference - March 26th, 2024
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results - March 26th, 2024
- QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system - March 26th, 2024
- Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights - March 26th, 2024
- Agile Therapeutics Announces Delisting from Nasdaq - March 26th, 2024
- Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - March 26th, 2024
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA... - March 26th, 2024
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection - March 26th, 2024
- CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion - March 26th, 2024
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia - March 26th, 2024
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - March 26th, 2024
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results - March 18th, 2024
- Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 18th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 18th, 2024
- Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 18th, 2024
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 18th, 2024
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 18th, 2024
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 18th, 2024
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 18th, 2024
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 18th, 2024
- Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 18th, 2024
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 18th, 2024
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 18th, 2024
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 18th, 2024
- Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 18th, 2024
- NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 18th, 2024
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - March 18th, 2024
- Financière de Tubize - Annual report 2023 - March 18th, 2024
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - March 18th, 2024
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration - March 18th, 2024
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results - March 10th, 2024
- Arbutus to Participate in Two Upcoming Investor Conferences - March 10th, 2024
- SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships - March 10th, 2024
- Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update - March 10th, 2024
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early... - March 10th, 2024
- Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights - March 10th, 2024
- DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document - March 10th, 2024
- Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award - March 10th, 2024
- Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program - March 10th, 2024
- Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of... - March 10th, 2024
- Evn Introduces a Game-Changer in Cannabis Edibles with New Hemp-Derived Live Resin Gummies - March 10th, 2024
- Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease - March 10th, 2024
- NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel - March 10th, 2024
- Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference - March 10th, 2024
- Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates - March 10th, 2024
- Better Choice Company To Effectuate a Reverse Stock Split - March 10th, 2024
- PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update - March 10th, 2024
- Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD... - March 10th, 2024
- Ultimovacs ASA: Mandatory notification of trades by primary insider - March 10th, 2024
- New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction - March 10th, 2024
- Mendus to hold Business Update event on March 12 - February 24th, 2024
- Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions - February 24th, 2024
- Castellum, Inc. Announces Closing of $4 Million Revolver with Live Oak Bank - February 24th, 2024
- Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP - February 24th, 2024
- BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat)... - February 24th, 2024
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy - February 24th, 2024
- Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - February 24th, 2024
- Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR® - February 24th, 2024
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update - February 24th, 2024
- Ocuphire Pharma to Present in the BIO CEO & Investor Conference - February 24th, 2024
- Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business - February 24th, 2024
- Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update - February 24th, 2024
- Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual... - February 24th, 2024
- Curia Appoints Steve Lavezoli as Vice President, Biologics - February 24th, 2024
- Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report - February 24th, 2024
- Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany - February 24th, 2024
- Starton Therapeutics to Present at BIO CEO & Investor Conference 2024 - February 24th, 2024
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - February 24th, 2024
- Celularity Announces 1-for-10 Reverse Stock Split - February 24th, 2024
- Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free... - February 24th, 2024